Abstract: Embodiments of the disclosure are drawn to apparatuses and methods for transmission beamforming. A multiphase beam steering transmitter may include a transmitter array of multiple transmitters. A transmitter may include a multiphase logic decoder that directly controls a power amplifier to perform a vector addition of a beam phase and amplitude. A transmitter of the array may include a multiphase clock generator that outputs basis phases with embedded phase modulation data which are output to the multiphase logic decoder. The multiphase clock generator may receive a modulated clock signal. The PA may be a multiphase switched capacitor power amplifier. The multiphase logic decoder may output two phases adjacent to a desired phase as inputs to clocks of the SCPA. The multiphase logic decoder may further output a control signal that determines which cells in the SCPA are activated and when.

Abstract: A method for reducing artifacts in magnetic resonance imaging (MRI) data includes acquiring a k-space dataset of an anatomical subject using a MRI scanner. An iterative compressed sensing reconstruction method is used to generate a reconstructed image based on the k-space dataset. This iterative compressed sensing reconstruction method uses (a) L1-norm based total variation constraints applied the temporal and spatial dimensions of the k-space dataset and (b) a low rank constraint. After the reconstructed image is generated, a deep learning network is used to generate an artifact image depicting motion artifacts present in the reconstructed image. The reconstructed image is subtracted from the artifact image to yield a final image with the motion artifacts removed.

Abstract: Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (PRR) antagonist. In some instances the PRR antagonist is a polypeptide. The PRR antagonist can be a polypeptide having at least 70% identity to the amino acid sequence set forth in SEQ ID NO:2. Also disclosed are methods of decreasing proteinuria and methods of promoting wound healing by administering a PRR antagonist.

Abstract: A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen. In addition, the nerve conduit includes at least one drug reservoir to hold agent(s) that may, for example, facilitate nerve regeneration. The drugs diffuse from the drug reservoir(s) into the nerve repair conduit through an outlet (e.g., a semipermeable membrane) in proximity to the first and second portions of a selected nerve. The nerve repair conduit may be configured to deliver the agent(s) at a rate having substantially zero-order kinetics and/or at a constant rate over a selected period of time (e.g., at least 1 week).

Abstract: Disclosed herein are compositions and methods for inhibiting respiratory syncytial virus (RSV) entry into a host cell. Also provided herein are methods of identifying a peptide that interacts with the N-trimer of RSV F protein.

Abstract: An implantable cardioverter defibrillator (ICD) and methods of detection and treatment of dangerous and life-threatening heart rhythms by delivering real-time, customized low-energy pacing pulses to specific anatomy in the heart. The ICD includes a power source, a controller, powered by the power source, including an electronic processor, a memory, and a signal generator. The ICD also includes a lead coupled to the controller and an electrode that is in electrical communication with a His-bundle of a patient's heart. The ICD detects a ventricular arrhythmia of the patient's heart using the controller, and is configured to provide a pulsed defibrillation signal to the electrode to terminate the ventricular arrhythmia.

Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: The disclosure provides recombinant cells and methods for producing a ribosomally synthesized and posttranslationally modified peptide (RiPP), as well as RiPP libraries and methods for producing RiPP libraries.

Abstract: An organic light-emitting apparatus includes an organic light-emitting device and a magnetic field-applying member that applies a magnetic field to the organic light-emitting device. The organic light-emitting device includes a host and a dopant.

Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.

Abstract: Methods and containers are provided for identifying a species, illustratively a bacterial species. Illustrative methods comprise amplifying various genes in the nucleic acid from the bacterial species in a single reaction mixture using pairs of outer first-stage primers designed to hybridize to generally conserved regions of the respective genes to generate a plurality of first-stage amplicons, dividing the reaction mixture into a plurality of second-stage reactions, each using a unique pair of second-stage primers, each pair of second-stage primers specific for a target bacterial species or subset of bacterial species, detecting which of the second-stage reactions amplified, and identifying the bacterial species based on second-stage amplification.

Abstract: Methods and systems are described for treatment of atrial fibrillation. Certain embodiments provide methods of assessing a risk of thromboembolic stroke in a patient. The method comprises acquiring image data and determining an indicator of a degree of fibrosis of a patient's left atrium (LA) based on the image data. A treatment modality is then determined and administered to the patient based on the analysis of the image data.

Abstract: A fluid analysis device including a fluid receipt chamber, a first capacitive element for measuring fluid flow into the fluid receipt chamber and a controller operatively coupled to the first capacitive element, wherein the controller is configured to measure a first capacitance of the first capacitive element.

Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.

Abstract: Functionalized nanotube arrays, sensors, and related methods of detecting target compounds are presented. A functionalized nanotube array can include a plurality of metal oxide nanotubes. The metal oxide nanotubes can be formed of a metal oxide and can have an interior or exterior surface that is optionally functionalized with at least one metal ion. These metal nanotubes can be used in a sensor for detecting target compounds such as volatile organic compounds, and biomarkers in a fluid environment. The sensor can further include a power source configured to apply a voltage to the nanotube array and a current sensor configured to monitor and detect changes in a response current which varies upon binding with the target compounds.

Abstract: A system for measuring the blood loss comprises a measuring device that determines the hemoglobin concentration of fluid within a container utilizing a light source and a light detector. The container receives blood and other fluids from a patient during a medical procedure. Light from the light source is passed through the blood and other fluids in the container and is detected by the light detector. Based upon a magnitude of light detected, the hemoglobin concentration of the fluid in the container can be determined. A volume-measuring device determines the volume of blood and fluid in the container. Knowing the hemoglobin concentration and volume of fluid in the container, the volume of patient blood loss in the container can be determined. The blood loss measuring device in combination with infusion systems maintains a real-blood volume status so that proper infusion of blood, crystalloid and/or colloid solutions occurs.

Abstract: A method (500) for producing a titanium product is disclosed. The method (500) can include obtaining TiO2-slag (501) and reducing impurities in the TiO2-slag (502) to form purified TiO2 (503). The method (500) can also include reducing the purified TiO2 using a metallic reducing agent (504) to form a hydrogenated titanium product comprising TiH2 (505). The hydrogenated titanium product can be dehydrogenated (506) to form a titanium product (508). The titanium product can also be optionally deoxygenated (507) to reduce oxygen content.